A more ethical way to compare epilepsy treatments

December 5, 2011

For the first time, a new research methodology recently approved by the Food and Drug Administration has been used to demonstrate that converting patients from one anti-epileptic drug to another - in this case, lamotrigine extended-release (LTG XR) - is well-tolerated, effective and safe. The work by Jacqueline French and her team, from New York University in the US, illustrates how the new methodology addresses ethical issues inherent in more traditional study designs. It is published online in Springer's journal, Neurotherapeutics.

The use of traditional control groups in experimental designs can raise some ethical concerns, such as using inferior treatments for the control group in the study of an illness with significant morbidity and mortality, such as epilepsy. What French and team have done is compare their - the one where they are moving patients from one drug to another - with a so-called 'historical control group' obtained from a dataset of eight previously published studies, rather than recruit a new control group and give them a potentially less effective drug.

In their study, a total of 226 patients aged 13 years or older undergoing treatment for epilepsy across seven countries were randomly allocated to one of two groups: the first group received LTG XR 250mg; the second received 300mg once daily. During the conversion phase (11-12 weeks), the LTG XR dose was increased progressively as the previous drug was withdrawn gradually. The subjects then had a 12-week maintenance phase with LTG XR as . Throughout the study period, the researchers monitored both the type and frequency of seizures and compared them to pre-intervention assessments.

The results demonstrate that LTG XR is effective as monotherapy. Approximately half of the experienced at least a 50 percent reduction in compared to the number recorded before the study. More than half the group reported minor adverse events, including headache and dizziness predominantly.

The authors conclude: "A conversion-to-monotherapy study like ours, which incorporates a historical control, provides important information to clinicians, who often wish to convert their patients from one anti-epileptic drug to another. Without putting a group of patients at undue risk of seizure worsening, we demonstrated that it is possible to convert patients from another drug to LTG XR and that this conversion is well tolerated."

Explore further: New drug may reduce seizures in epilepsy

More information: French J et al (2011). Lamotrigine XR conversion to monotherapy: first study using a historical control group. Neurotherapeutics. DOI 10.1007/s13311-011-0088-3

Related Stories

New drug may reduce seizures in epilepsy

April 13, 2011

A new drug called perampanel appears to significantly reduce seizures in people with hard-to-control epilepsy, according to results of the first clinical trial to test the higher 12 mg dose of the drug. The late-breaking ...

Recommended for you

Brain activity may predict risk of falls in older people

December 7, 2016

Measuring the brain activity of healthy, older adults while they walk and talk at the same time may help predict their risk of falls later, according to a study published in the December 7, 2016, online issue of Neurology.

Knowing one's place in a social hierarchy

December 7, 2016

When you start a new job, it's normal to spend the first day working out who's who in the pecking order, information that will come in handy for making useful connections in the future. In an fMRI study published December ...

Deep brain stimulation may not boost memory

December 7, 2016

Deep brain stimulation (DBS) of areas in the brain known to be involved in making memories does not improve memory performance, according to a study by Columbia University researchers published December 7 in Neuron. The study ...

When neurons are 'born' impacts olfactory behavior in mice

December 7, 2016

New research from North Carolina State University shows that neurons generated at different life stages in mice can impact aspects of their olfactory sense and behavior. The work could have implications for our understanding ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.